Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer

BMC Urology

Volumn 8, Issue 1, 2008, Pages

  Ather, M Hammad ^a   Abbas, Farhat ^a   Faruqui, Nuzhat ^a   Israr, Mohammad ^a   Pervez, Shahid ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; SYNAPTOPHYSIN; ENOLASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DISEASE MARKER; DISTANT METASTASIS; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; RADICAL RETROPUBIC PROSTATECTOMY; TRANSURETHRAL RESECTION; CHEMISTRY; DISEASE COURSE; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR;

AGED; CHROMOGRANIN A; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; SYNAPTOPHYSIN; TUMOR MARKERS, BIOLOGICAL;

EID: 58649103729     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-8-21     Document Type: Article

References (21)

1. Cancer statistics, 2007. A Jemal R Siegel E Ward T Murray J Xu MJ Thun, CA Cancer J Clin 2007 57 43 66 17237035
2. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. PA di Sant'Agnese, Cancer 1992 70 254 68 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E 1350941
3. Prostate tissue factors. DG Bostwick CS Foster F Algaba RVP Hutter R Montironi FK Mostofi, Prostate cancer. Second international consultation on prostate cancer Plymouth: Plymbridge Distributors, Murphy G, Denis L, Khoury S, Partin A, Denis L, 2000 162 201
4. Prognostic and Therapeutic Value Neuro Endocrine Differentiation as Manifested by Circulating Chromogranin A in Prostate Carcinoma. MH Ather AH Shariff, Prostate cancer Nova science Publishers, New York, US, John N Lucas
5. Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage. MH Ather F Abbas N Faruqui M Israr S Pervez, BMC Urol 2004 4 14 17 15588310 10.1186/1471-2490-4-14
6. Prostate cancer: are new prognostic markers on the horizon? M Lijovic ME Fabiani J Bader AG Frauman, Prostate Cancer Prostatic Diseases 2000 3 62 5 10.1038/sj.pcan.4500408
7. Precursors of prostate cancer, progression, regression and chemoprevention. R Montironi CC Schulman, Eur Urol 1996 30 133 7 8875193
8. Divergent neuroendocrine differentiation in prostatic carcinoma. PA Di Sant'Agnese, Semin Diagn Pathol 2000 17 2 149 61 10839615
9. N Kamiya H Suzuki K Kawamura T Imamoto Y Naya N Tochigi Y Kakuta K Yamaguchi H Ishikura T Ichikawa, Int J Urol 2008 15 423 8 10.1111/j.1442-2042. 2008.02015.x 18452460
10. A.P.U.D. type endocrine tumour of the prostate. Incidence and prognosis in association with adenocarcinoma. MC Dauge V Delmas, Prog Clin Biol Res 1987 243A 529 31 2889216
11. Neuro-endocrine cells - a new prognostic parameter in prostate cancer. RJ Cohen G Glezerson Z Haffejee, Br J Urol 1991 68 258 62 10.1111/j.1464-410X. 1991.tb15318.x 1913066
12. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. DG Bostwick MK Dousa BG Crawford PC Wollan, Am J Surg Pathol 1994 18 1240 6 7977947
13. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. MA Noordzij TH van der Kwast GJ van Steenbrugge WJ Hop FH Schroder, Int J Cancer 1995 62 252 8 10.1002/ijc.2910620304 7543077
14. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. PA Abrahamsson AT Cockett PA di Sant'Agnese, Prostate Suppl 1998 8 37 42 10.1002/(SICI)1097-0045(1998)8+<37::AID- PROS7>3.0.CO;2-D 9690662
15. Detection of prostate cancer and predicting progression: Current and future diagnostic markers. JV Tricoli M Schoenfeldt BA Conley, Clin Cancer Res 2004 10 3943 3953 10.1158/1078-0432.CCR-03-0200 15217924
16. Practical markers used in the diagnosis of neuroendocrine tumors. RV Lloyd, Endocr Pathol 2003 14 293 301 10.1385/EP:14:4:293 14739487
17. Pretreatment serum level of neuron specific enolase (NSE)as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. N Kamiya K Akakura H Suzuki S Isshiki A Komiya T Ueda H Ito, Eur Urol 2003 44 309 314 10.1016/S0302-2838(03)00303-8 12932928
18. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. S Isshiki K Akakura A Komiya H Suzuki N Kamiya H Ito, J Urol 2002 167 512 515 10.1016/S0022-5347(01)69075-X 11792908
19. Prognostic significance of plasma Chromogranin A levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. ME Taplin DJ George S Halabi B Sanford PG Febbo KT Hennessy CG Mihos NJ Vogelzang EJ Small PW Kantoff, Urology 2005 66 386 391 10.1016/j.urology.2005. 03.040 16098367
20. Neuroendocrine carcinomas of the prostate and urinary bladder: A diagnostic and therapeutic challenge. B Helpap G Kloppel, Virchows Arch 2002 440 241 248 10.1007/s00428-001-0583-8 11889593
21. Practical markers used in the diagnosis of endocrine tumors. LA Erickson RV Lloyd, Adv Anat Pathol 2004 11 175 189 10.1097/01.pap.0000131824.77317.a7 15220821